EURONOVA - A Multicentric European Study on ProNOVA Sirolimus Eluting Stent

Prof Thomas Ischinger M D, F E S C, F A C C Munich Hospital, Germany TCT 2006

Number of patients enrolled – 300

Inclusion Criteria

  • Patients above 18 years of age
  • Denova coronary lesions ≤ 30mm
  • One or multiple vessels of 2.5mm-3.5mm in diameter
  • Patients who consented for the study were enrolled

Exclusion Criteria

  • Patients with evolving MI
  • Patients with prior CABG


  • Total patients enrolled - 65
  • Total number of stents - 77

In Hospital MACE

6 Months MACE


Pronova stent is safe and effective in European population.